AptarGroup, Inc. designs and manufactures drug and consumer product dosing, dispensing, and protection technologies. The company operates through three reporting segments: Pharma, Beauty, and Closures. Its primary products include dispensing pumps, closures, aerosol valves, elastomeric primary packaging components, active material science solutions, and digital health solutions. Aptar serves end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. The company supplies customers in North America, Europe, Asia, and Latin America. Aptar’s business originated in the late 1940s with the manufacturing of aerosol valves. Recent acquisitions include Sommaplast, BTY, and Goldrain.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Specialty Chemicals Homepage aptar.com
Sector Basic Materials IR page investors.aptar.com/overview/default.aspx
Tags
drug delivery, dispensing systems, aerosol valves, pharmaceutical packaging, cosmetic packaging, digital health, elastomeric components, active material science, Sommaplast, BTY, Goldrain, Ningbo Jinyu Technology Industry Co. Ltd.
Press page —

Metrics

Valuation  
Market cap $ 9B
Market cap (USD) $ 9B
P/E 34.46
PEG 1.92
P/BV 3.44
P/S 2.26
P/OCF 15.69
P/FCF 30.54
Dividend yield 1.4%
Turnover / mcap —
Returns  
ROE 15.3%
ROI 9.5%
ROIC 9.6%
Profit margin 10.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 18.0%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 55.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score 22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 3.777B 3.583B 3.487B 3.322B 3.227B 2.929B 2.86B 2.765B 2.469B 2.331B 2.317B 2.598B 2.52B 2.346B 2.356B 2.077B 1.842B 2.072B 1.892B — 1.38B 1.297B 1.115B 926.691M 891.986M 883.481M
Net profit 392.789M 374.541M 284.487M 239.288M 243.638M 214.09M 242.227M 194.766M 220.029M 205.604M 199.295M 191.624M 171.926M 162.42M 183.63M 173.481M 124.623M 153.495M 141.739M 102.896M 100.034M 93.287M 79.679M 66.647M 58.844M 64.666M
Free cash flow 299.58M 366.932M 262.897M 168.19M 55.508M 324.199M 272.181M 102.376M 168.105M 198.207M 175.192M 152.611M 133.926M 139.839M 81.35M 142.911M 148.665M 66.611M 135.519M 89.798M 89.627M 63.48M 62.511M 64.674M 35.657M 33.865M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 121.96 157.1 123.62 109.98 122.48 136.89 115.62 94.07 86.28 73.45 72.65 66.84 67.81 47.73 52.19 47.58 35.73 30.27 39.85 59.8 52.5 — — — — —
Price performance 12m -0.22 0.27 0.12 -0.1 -0.11 0.18 0.23 0.09 0.17 0.01 0.09 -0.01 0.42 -0.09 0.1 0.33 0.18 -0.24 -0.33 0.14 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 433M 510M 570M 558M 567M 671M 677M 678M 658M 804M
↳ YoY growth +10.6% +17.8% +11.6% -2.0% +1.5% +18.3% +0.9% +0.1% -2.9% +22.1%
↳ 5y CAGR +2.2% +5.2% +5.4% +6.5% +7.7% +9.1% +5.8% +3.5% +3.3% +7.2%
Borrowings, current (USD) 169M 4.34M 101M 44.3M 52.2M 147M 3.81M 81.8M 176M 184M
Borrowings, non-current (USD) 773M 1.19B 1.13B 1.09B 1.05B 907M 1.05B 681M 688M 1.14B
Lease liabilities (USD) — — 61.3M 102M 101M 93.6M 86.9M 85.8M 90.5M 91M
Cash and deposits (USD) 466M 713M 262M 242M 300M 123M 142M 224M 224M 402M
Intangible assets (USD) 94.5M 95.5M 255M 291M 344M 362M 316M 283M 255M 255M
Right-of-use assets (USD) — — 83.2M 72.4M 69.8M 62.5M 58.7M 59.1M 64.2M 65.7M
Net debt (borrowings + leases - cash) (USD) 476M 483M 965M 990M 908M 1.02B 1B 625M 731M 1.01B
Cash flow detail
Operating cash flow (USD) 327M 325M 314M 514M 570M 363M 479M 575M 643M 570M
Purchases of property, plant and equipment (USD) -129M -157M -211M -242M -246M -308M -310M -312M -276M -270M
Purchases of intangible assets (USD) -2.49M — -611,000 -4.81M -6.09M 0.00 -5.19M -6.06M -17.7M -5.02M
Change in receivables (cash effect) (USD) -41.7M -44.7M -67M 8.81M 13.5M -123M — — — —
Change in inventories (cash effect) (USD) -834,000 -13M -25.2M 605,000 13.7M -80M -60.4M -10.6M 21.9M -10.6M
Change in payables (cash effect) (USD) -12.5M 58.2M 37.2M -779,000 65.6M 52.3M 55.1M 14.6M -23.7M -18.3M
Dividends paid (cash effect) (USD) -76.7M -79.9M -82.3M -90.2M -92.7M -98.5M -99.5M -104M -114M -121M
Share buybacks (cash effect) (USD) — -121M -3.91M -86.5M 0.00 -78.1M -92.1M -47.6M -68.6M -365M
Interest paid (cash effect) (USD) -36.3M -38.8M -32M -34.4M -33.3M -29.1M -35.5M -39.6M -43.5M -50M
Income taxes paid (cash effect) (USD) -82.2M -77.3M -96M -86.1M -93.6M -95M -87.5M -112M -89.4M -179M
Share-based compensation (USD) 19.8M 18.9M 19.6M 23.9M 34.1M 38.9M 40.9M 41.3M 47.7M 43.9M
Operating cash flow before change in receivables (USD) 369M 369M 381M 506M 557M 487M — — — —
Free cash flow (OCF - PPE - intangibles) (USD) 196M 168M 102M 267M 318M 55.5M 163M 257M 349M 295M
Income detail
Research and development expense (USD) 66.2M 68.2M 75.3M 82.8M 92.5M 99.8M 93.5M 92.8M 96.1M 105M
↳ 5y CAGR -0.2% +0.8% +1.0% +1.7% +6.6% +8.6% +6.5% +4.3% +3.0% +2.6%
Total comprehensive income (USD) 148M 286M 144M 211M 274M 209M 213M 317M 254M 636M
Comprehensive income to owners (USD) 148M 286M 144M 211M 274M 210M 214M 317M 254M 636M
Provision for credit losses (USD) 561,000 235,000 923,000 782,000 865,000 1.6M 3.21M 8.08M 1.02M 1.3M
Credit cost ratio (credit losses / average receivables) (%) 0.1% 0.0% 0.2% 0.1% 0.2% 0.3% 0.5% 1.2% 0.2% 0.2%
Reported Feb 27, 2017 Feb 26, 2018 May 1, 2019 Feb 24, 2020 Feb 19, 2021 Feb 18, 2022 Feb 17, 2023 Feb 9, 2024 Feb 7, 2025 Feb 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Aptar Increases Quarterly Dividend to $0.50 Per Share Bull 3 Bear 0 Capital return

October 29, 2026

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its Board of Directors declared a quarterly cash dividend of $0.50 per share, an increase of approximately 4% from the previous quarterly dividend of $0.48 per share. The payment date is December 3, 2026, to stockholders of record as of November 12, 2026.

“Increasing our dividend to $0.50 per share puts Aptar on track for its 33rd consecutive year of paying an annually increasing dividend and reflects our confidence in the Company’s future growth,” said Gael Touya, President and Chief Executive Officer. “As we invest in the business to drive profitable growth, we remain focused on disciplined capital allocation and creating sustainable, long-term value for our shareholders.”

About Aptar

Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com .

This press release contains forward-looking statements, including with regard to the payment of the quarterly cash dividend, future dividend increases and the Company’s future growth and capital allocation. Expressions or future or conditional verbs such as “will,” and words such as “on track,” “future” and similar expressions, are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the discretion of our Board of Directors to declare any future dividend, which will depend on factors including our earnings, cash flows, financial condition, capital requirements and such other factors our Board of Directors considers relevant; the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

**Investor Relations Contact:
**Mary Skafidas
[email protected]

+1 347-351-6407

Media Contact:
Katie Reardon
[email protected]

+1 815-479-5671

Source: AptarGroup, Inc.

View All News

Aptar Logo

Follow us

X, twitter    linkedin    youtube    instagram    facebook

IR Contact

Investor Relations Department
AptarGroup, Inc.
265 Exchange Drive, Suite 301
Crystal Lake, IL 60014

​ 815-477-0424

​ [email protected]

Investor Email Alerts

Personal Information.

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

  • News
  • Quarterly Reports
  • Annual Reports
  • SEC Filings
  • End of Day Stock Quote
  • Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again. Submit

Unsubscribe

© 2026 Q4 Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Aptar Reports Third Quarter 2026 Results Bull 3 Bear 0 Results

October 29, 2026

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today reported the following third quarter results for the period ended September 30, 2026, as compared to the corresponding period of the last fiscal year.

Aptar Reports Third Quarter 2026 Results

Aptar Reports Third Quarter 2026 Results

Third Quarter 2026 Highlights

(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)

  • Reported sales increased 6% and core sales increased 5%
  • Reported net income was $33 million and reported earnings per share were $0.51, impacted by deconsolidation of the Russian subsidiary
  • Adjusted earnings per share were $1.52, at the higher end of the guidance range, compared to $1.62 in the prior year period at comparable exchange rates
  • Adjusted EBITDA margin was 21.3%, compared to 23.2% in the prior year quarter
  • Returned $61 million in the quarter and $272 million year-to-date to shareholders through share repurchases and dividends
  • Subsequent to the quarter, the Board of Directors approved an increase in the quarterly cash dividend from $0.48 to $0.50

“We delivered broad-based revenue growth across all three segments. Pharma delivered impressive growth in central nervous system therapies, pulmonary, injectables and consumer healthcare, while maintaining profitability at the high end of our long-term target range. Our Pharma pipeline remains strong, with continued focus on building the pipeline and converting opportunities into future growth. New technologies and development programs are expanding the role we can play with customers across the drug development cycle. Beauty and Closures also delivered strong top-line growth, including double-digit core sales growth in Closures, where innovation in beverage dispensing continues to gain momentum. As I begin my tenure as CEO, our direction is clear: deepen our position with customers, accelerate innovation, execute with greater consistency and allocate capital thoughtfully. These priorities will guide how we drive profitable growth and create long-term value for Aptar and our shareholders,” said Gael Touya, Aptar President and CEO.

Third Quarter Results

For the quarter ended September 30, 2026, reported sales increased 6% to $1.02 billion compared to $961 million in the prior year and core sales increased 5% compared to the prior year period.

Third Quarter Segment Sales Analysis
(Change Over Prior Year)
Pharma Beauty Closures Total AptarGroup
Reported Sales Growth 2% 9% 11% 6%
Currency Effects(1) 1% 0% (1)% 0%
Acquisitions / Deconsolidation (2)% (1)% 1% (1)%
Core Sales Growth 1% 8% 11% 5%
(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

Pharma’s reported sales increased 2% compared to the prior year period and core sales increased 1%. Adjusting for emergency medicine destocking, Pharma delivered 8% core sales growth in the quarter. Performance was supported by continued growth across a number of end markets, including central nervous system and pulmonary therapies, nasal decongestants, eye care and dermal drug delivery solutions, and demand related to biologics, vaccines and GLP-1 therapies. These growth drivers were partially offset by the anticipated reduction in emergency medicine sales. Pharma delivered adjusted EBITDA margin of 36.4% a decline of 80 basis points, remaining above our long-term target despite a short-term unfavorable product mix related to destocking. Royalties and productivity improvements continued to positively impact margins.

Beauty’s reported sales increased 9% when compared to the prior year period, with core sales growth of 8%. There was increased demand for prestige fragrance dispensing, color cosmetics, as well as hair care applications, and pass throughs of higher input costs also contributed positively. Adjusted EBITDA margin was 11.4%, a decline of 70 basis points, including unfavorable mix and ongoing challenges in North American operations.

Closures’ reported sales rose 11% from the prior year period, with core sales growth of 11%. Beverage and food sales grew significantly, led by strong demand for bottled water and concentrates, continued momentum from our latest beverage dispensing closure innovation, as well as strong condiment sales. Pass throughs of higher input costs contributed positively to core sales growth, however, the dilutive impact drove the decline of 60 basis points in Adjusted EBITDA margin to 15.5%.

During the third quarter, Aptar deconsolidated its Russian subsidiary following a governmental decree placing the subsidiary under external administration and the resulting loss of control. Aptar recorded a $58.0 million loss on deconsolidation which included approximately $30.0 million of cash held by the subsidiary. The combined impact was $61.2 million before tax, including approximately $2.6 million of related receivable reserves and $0.5 million of related legal costs; and $60.4 million after tax, or $0.94 per diluted share.

Reported third quarter earnings per share were $0.51 compared to $1.92 reported a year ago. Adjusted earnings per share were $1.52, compared to the prior year period’s adjusted earnings per share of $1.62, including comparable exchange rates. The third quarter reported effective tax rate was 45.6%, reflecting the non-deductible tax impact of the deconsolidation of the Russian subsidiary. The adjusted effective tax rate was 23.4%, compared to the prior year period’s reported effective tax rate of 17.1% and adjusted effective tax rate of 20.8%.

Nine Months Year-to-Date Results

For the nine months ended September 30, 2026, reported sales increased 8% to $3.03 billion compared to $2.81 billion in the prior year and core sales increased 2%.

Nine Months Year-To-Date Segment Sales Analysis
(Change Over Prior Year)
Pharma Beauty Closures Total AptarGroup
Total Reported Sales Growth 4% 12% 7% 8%
Currency Effects(1) (3)% (4)% (3)% (4)%
Acquisitions / Deconsolidation (1)% (4)% 1% (2)%
Core Sales Growth 0% 4% 5% 2%
(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

For the nine months ended September 30, 2026, Aptar’s reported earnings per share were $3.00, a decrease of 37%, which was also impacted by the deconsolidation of the Russian subsidiary, compared to $4.75 reported a year ago. For the first nine months of 2026, adjusted earnings per share were $4.13 and decreased 10% from prior year adjusted earnings per share of $4.60, including comparable exchange rates. The current year had a reported effective tax rate of 28.1% and an adjusted effective tax rate of 23.2% compared to the prior year reported and adjusted effective tax rates of 20.4% and 21.9%, respectively.

Outlook

Regarding Aptar’s outlook, Touya stated, “We expect Aptar to finish the year strong, supported by continued Pharma growth, particularly in consumer healthcare and injectables and without the headwind from emergency medicine destocking. Our Pharma pipeline remains strong, with new technologies and development programs expanding our reach across therapeutic areas and advancing opportunities for future growth. Closures continues its great momentum, with innovation helping drive increased demand, particularly for our beverage technologies. In Beauty, we remain focused on improving our long-term North American trajectory, while we continue to see pockets of healthy demand in areas, such as prestige fragrance, globally.”

Aptar currently expects adjusted earnings per share for the fourth quarter of 2026 to be in the range of $1.39 to $1.47. This guidance assumes an effective tax rate range of 17.5% to 19.5%. The earnings per share guidance range is assuming a 1.12 Euro to USD exchange rate.

Cash Dividends and Share Repurchases

During the third quarter, Aptar repurchased approximately 234 thousand shares for $30 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. As previously announced, Aptar’s Board of Directors approved a quarterly cash dividend of $0.50 per share. The payment date is December 3, 2026, to stockholders of record as of November 12, 2026.

Open Conference Call

There will be a conference call held on Friday, October 30, 2026 at 8:00 a.m. Central Time to discuss the company’s third quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

About Aptar

Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com .

Presentation of Non-GAAP Information

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments, gains from remeasurement of equity method investments and net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Core sales also exclude material acquisitions and, for the three and nine months ended September 30, 2026, the Russian subsidiary’s net sales from both periods. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, purchase accounting adjustments related to acquisitions and investments, gains from remeasurement of equity method investments, net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. Russia deconsolidation impacts comprise the loss on deconsolidation of our Russian subsidiary and related receivable reserves and legal costs described above, which we exclude because they resulted from a government action rather than from the operations of our businesses and therefore do not reflect the underlying performance of our remaining operations. For the three and nine months ended September 30, 2026 and 2025, “Other special items” include costs incurred related to non-ordinary-course litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to “Legal Proceedings” within Note 13 - Commitments and Contingencies within Aptar’s Form 10-K for the year ended December 31, 2025 and subsequent SEC filings for more information. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of our routine activities, such as restructuring initiatives, acquisition-related costs and other special items.

This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries and certain supply chain disruptions; as well as governmental actions affecting our foreign operations and assets, including the loss of control over, and our ability to recover value from, our Russian operations; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to keep pace with competition and technological advances, including in connection with the shifting of Pharma origination to less regulated markets; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate and cash flow; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key products or accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, interest rate volatility; loss of royalty revenue due to contract expirations; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(In Thousands, Except Per Share Data)
Consolidated Statements of Income
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Net Sales $ 1,019,119 $ 961,131 $ 3,028,495 $ 2,814,445
Cost of Sales (exclusive of depreciation and amortization shown below) 646,196 598,046 1,938,146 1,747,931
Selling, Research & Development and Administrative 160,164 148,760 485,501 455,176
Depreciation and Amortization 75,544 75,234 230,910 210,785
Restructuring Initiatives 2,208 2,168 4,713 5,789
Operating Income 135,007 136,923 369,225 394,764
Other Income (Expense):
Interest Expense (15,790 ) (13,532 ) (48,733 ) (35,733 )
Interest Income 1,930 2,400 8,359 7,094
Net Investment (Loss) Gain (1,011 ) (161 ) (1,160 ) 845
Loss on Russia Deconsolidation (58,020 ) — (58,020 ) —
Equity in Results of Affiliates 1,106 1,747 3,224 6,142
Gain from Remeasurement of Equity Method Investment — 26,518 — 26,518
Miscellaneous Expense, net (2,889 ) 232 (3,744 ) 226
Income before Income Taxes 60,333 154,127 269,151 399,856
Provision for Income Taxes 27,511 26,295 75,552 81,629
Net Income $ 32,822 $ 127,832 $ 193,599 $ 318,227
Net (Income) Loss Attributable to Noncontrolling Interests (226 ) (47 ) (382 ) 76
Net Loss (Income) Attributable to Redeemable Noncontrolling Interests 6 142 (368 ) 142
Net Income Attributable to AptarGroup, Inc. $ 32,602 $ 127,927 $ 192,849 $ 318,445
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic $ 0.51 $ 1.95 $ 3.03 $ 4.83
Diluted $ 0.51 $ 1.92 $ 3.00 $ 4.75
Average Numbers of Shares Outstanding:
Basic 63,523 65,709 63,733 65,989
Diluted 64,147 66,630 64,373 67,043
AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(continued)
($ In Thousands)
Consolidated Balance Sheets
September 30, 2026 December 31, 2025
ASSETS
Cash and Equivalents $ 204,176 $ 402,424
Short-term Investments 8,121 7,109
Accounts and Notes Receivable, Net 883,939 803,830
Inventories 582,605 537,845
Prepaid and Other 157,950 142,354
Total Current Assets 1,836,791 1,893,562
Property, Plant and Equipment, Net 1,635,530 1,676,479
Goodwill 1,067,152 1,077,898
Other Assets 572,153 604,780
Total Assets $ 5,111,626 $ 5,252,719
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY
Short-Term Obligations $ 350,681 $ 343,531
Accounts Payable, Accrued and Other Liabilities 872,133 822,913
Total Current Liabilities 1,222,814 1,166,444
Long-Term Obligations 1,024,735 1,139,433
Deferred Liabilities and Other 202,894 234,617
Total Liabilities 2,450,443 2,540,494
Redeemable Noncontrolling Interests 28,048 26,244
Total Mezzanine Equity 28,048 26,244
AptarGroup, Inc. Stockholders' Equity 2,614,324 2,668,096
Noncontrolling Interests in Subsidiaries 18,811 17,885
Total Stockholders' Equity 2,633,135 2,685,981
Total Liabilities, Mezzanine Equity and Stockholders' Equity $ 5,111,626 $ 5,252,719
AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(continued)
($ In Thousands)
Consolidated Statement of Cash Flows
Nine Months Ended September 30, 2026 2025
Cash Flows from Operating Activities: ​ ​
Net income $ 193,599 $ 318,227
Adjustments to reconcile net income to net cash provided by operations:
Depreciation 198,044 177,412
Amortization 32,866 33,373
Stock-based compensation 33,043 36,772
Provision for CECL 4,374 516
Loss (gain) on disposition of fixed assets 484 77
Loss on Russia deconsolidation 58,020 —
Net loss (gain) on remeasurement of equity securities 1,160 (845 )
Deferred income taxes (5,257 ) (31,851 )
Defined benefit plan expense 6,898 10,232
Equity in results of affiliates (3,224 ) (6,142 )
Gain on remeasurement of equity method investment — (26,518 )
Impairment loss 5,007 —
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables (101,728 ) (66,812 )
Inventories (56,698 ) (22,782 )
Prepaid and other current assets (17,906 ) (28,064 )
Accounts payable, accrued and other liabilities 60,132 6,950
Income taxes payable (5,250 ) (1,281 )
Retirement and deferred compensation plan liabilities (6,183 ) (5,891 )
Retirement and deferred compensation plan assets 420 (7,314 )
Other changes, net (8,023 ) 247
Net Cash Provided by Operations 389,778 386,306
Cash Flows from Investing Activities:
Capital expenditures (191,965 ) (183,600 )
Proceeds from government grants — 3,308
Proceeds from sale of property, plant and equipment 1,544 2,103
(Purchases) and maturities of short-term investments (1,462 ) 2,813
Acquisition of business, net of cash acquired and release of escrow (156 ) (28,221 )
Acquisition of intangible assets, net (1,933 ) (4,301 )
Investment in equity securities — (7,258 )
Cash balance of deconsolidated subsidiary (29,977 ) —
Notes receivable, net 1,355 37
Net Cash Used by Investing Activities (222,594 ) (215,119 )
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts 20,826 2,105
Repayments of notes payable and overdrafts (21,281 ) (1,946 )
Proceeds of short term revolving credit facility, net 50,000 144,620
Proceeds from long-term obligations 6,112 1,204
Repayments of long-term obligations (160,897 ) (36,490 )
Payment of contingent consideration obligation (3,730 ) —
Dividends paid (92,054 ) (89,287 )
Proceeds from stock option exercises 22,420 14,869
Purchase of treasury stock (179,973 ) (190,005 )
Redeemable noncontrolling interest 1,106 703
Net Cash Used by Financing Activities (357,471 ) (154,227 )
Effect of Exchange Rate Changes on Cash (7,961 ) 16,253
Net Decrease in Cash and Equivalents and Restricted Cash (198,248 ) 33,213
Cash and Equivalents and Restricted Cash at Beginning of Period 404,849 223,844
Cash and Equivalents and Restricted Cash at End of Period $ 206,601 $ 257,057
AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
Three Months Ended September 30, 2026
Consolidated Pharma Beauty Closures Corporate& Other Net Interest
Net Sales $ 1,019,119 $ 453,970 $ 357,372 $ 207,777 $ — $ —
Reported net income $ 32,822
Reported income taxes 27,511
Reported income before income taxes 60,333 122,589 5,363 (22,985 ) (30,774 ) (13,860 )
Adjustments:
Restructuring initiatives 2,208 406 1,827 (25 ) —
Net investment loss 1,011 — — — 1,011
Russia deconsolidation impact 61,161 3,137 9,555 40,626 7,843
Other special items 3,095 3,095 — — —
Adjusted earnings before income taxes 127,808 129,227 16,745 17,616 (21,920 ) (13,860 )
Interest expense 15,790 15,790
Interest income (1,930 ) (1,930 )
Adjusted earnings before net interest and taxes (Adjusted EBIT) 141,668 129,227 16,745 17,616 (21,920 ) —
Depreciation and amortization 75,544 35,911 23,965 14,561 1,107
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 217,212 $ 165,138 $ 40,710 $ 32,177 $ (20,813 ) $ —
Reported net income margins (Reported net income / Reported Net Sales) 3.2 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 21.3 % 36.4 % 11.4 % 15.5 %
Three Months Ended September 30, 2025
Consolidated Pharma Beauty Closures Corporate& Other Net Interest
Net Sales $ 961,131 $ 445,410 $ 327,768 $ 187,953 $ — $ —
Reported net income $ 127,832
Reported income taxes 26,295
Reported income before income taxes 154,127 124,759 40,073 14,714 (14,287 ) (11,132 )
Adjustments:
Restructuring initiatives 2,168 919 550 702 (3 )
Net investment loss 161 — — — 161
Gain from remeasurement of equity method investment (26,518 ) — (26,518 ) — —
Transaction costs related to acquisitions 748 584 164 — —
Purchase accounting adjustments related to acquisitions and investments 1,148 — 1,148 — —
Other special items 4,400 4,400 — — —
Adjusted earnings before income taxes 136,234 130,662 15,417 15,416 (14,129 ) (11,132 )
Interest expense 13,532 13,532
Interest income (2,400 ) (2,400 )
Adjusted earnings before net interest and taxes (Adjusted EBIT) 147,366 130,662 15,417 15,416 (14,129 ) —
Depreciation and amortization 75,234 35,107 24,332 14,921 874
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 222,600 $ 165,769 $ 39,749 $ 30,337 $ (13,255 ) $ —
Reported net income margins (Reported net income / Reported Net Sales) 13.3 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 23.2 % 37.2 % 12.1 % 16.1 %
AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
Nine Months Ended September 30, 2026
Consolidated Pharma Beauty Closures Corporate& Other Net Interest
Net Sales $ 3,028,495 $ 1,350,697 $ 1,088,461 $ 589,337 $ — $ —
Reported net income $ 193,599
Reported income taxes 75,552
Reported income before income taxes 269,151 339,843 38,396 1,434 (70,148 ) (40,374 )
Adjustments:
Restructuring initiatives 4,713 345 4,545 311 (488 )
Net investment loss 1,160 — — — 1,160
Realized gain on investments included in net investment loss above 88 — — — 88
Russia deconsolidation impact 61,161 3,137 9,555 40,626 7,843
Transaction costs related to acquisitions 83 83 — — —
Purchase accounting adjustments related to acquisitions and investments 145 145 — — —
Other special items 10,899 10,899 — — —
Adjusted earnings before income taxes 347,400 354,452 52,496 42,371 (61,545 ) (40,374 )
Interest expense 48,733 48,733
Interest income (8,359 ) (8,359 )
Adjusted earnings before net interest and taxes (Adjusted EBIT) 387,774 354,452 52,496 42,371 (61,545 ) —
Depreciation and amortization 230,910 110,814 73,438 43,312 3,346
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 618,684 $ 465,266 $ 125,934 $ 85,683 $ (58,199 ) $ —
Reported net income margins (Reported net income / Reported Net Sales) 6.4 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 20.4 % 34.4 % 11.6 % 14.5 %
AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
Nine Months Ended September 30, 2025
Consolidated Pharma Beauty Closures Corporate& Other Net Interest
Net Sales $ 2,814,445 $ 1,297,466 $ 968,324 $ 548,655 $ — $ —
Reported net income $ 318,227
Reported income taxes 81,629
Reported income before income taxes 399,856 358,465 81,382 44,593 (55,945 ) (28,639 )
Adjustments:
Restructuring initiatives 5,789 1,177 1,571 2,944 97
Net investment gain (845 ) — — — (845 )
Gain from remeasurement of equity method investment (26,518 ) — (26,518 ) — —
Transaction costs related to acquisitions 1,092 584 508 — —
Purchase accounting adjustments related to acquisitions and investments 1,148 — 1,148 — —
Other special items 4,400 4,400 — — —
Adjusted earnings before income taxes 384,922 364,626 58,091 47,537 (56,693 ) (28,639 )
Interest expense 35,733 35,733
Interest income (7,094 ) (7,094 )
Adjusted earnings before net interest and taxes (Adjusted EBIT) 413,561 364,626 58,091 47,537 (56,693 ) —
Depreciation and amortization 210,785 100,424 65,869 41,943 2,549 —
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 624,346 $ 465,050 $ 123,960 $ 89,480 $ (54,144 ) $ —
Reported net income margins (Reported net income / Reported Net Sales) 11.3 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 22.2 % 35.8 % 12.8 % 16.3 %
AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Income before Income Taxes $ 60,333 $ 154,127 $ 269,151 $ 399,856
Adjustments:
Restructuring initiatives 2,208 2,168 4,713 5,789
Net investment loss (gain) 1,011 161 1,160 (845 )
Realized gain on investments included in net investment loss (gain) above — — 88 —
Russia deconsolidation impact 61,161 — 61,161 —
Gain from remeasurement of equity method investment — (26,518 ) — (26,518 )
Transaction costs related to acquisitions — 748 83 1,092
Purchase accounting adjustments related to acquisitions and investments — 1,148 145 1,148
Other special items 3,095 4,400 10,899 4,400
Foreign currency effects (1) (371 ) 9,866
Adjusted Earnings before Income Taxes $ 127,808 $ 135,863 $ 347,400 $ 394,788
Provision for Income Taxes $ 27,511 $ 26,295 $ 75,552 $ 81,629
Adjustments:
Restructuring initiatives 557 561 1,240 1,488
Net investment loss (gain) 247 39 284 (207 )
Realized gain on investments included in net investment loss (gain) above — — 22 —
Russia deconsolidation impact 785 — 785 —
Gain from remeasurement of equity method investment — — — —
Transaction costs related to acquisitions — 182 20 268
Purchase accounting adjustments related to acquisitions and investments — 172 49 172
Other special items 788 1,078 2,815 1,078
Foreign currency effects (1) (63 ) 2,014
Adjusted Provision for Income Taxes $ 29,888 $ 28,264 $ 80,767 $ 86,442
Net (Income) Loss Attributable to Noncontrolling Interests $ (226 ) $ (47 ) $ (382 ) $ 76
Net (Income) Loss Attributable to Redeemable Noncontrolling Interests $ 6 $ 142 $ (368 ) $ 142
Net Income Attributable to AptarGroup, Inc. $ 32,602 $ 127,927 $ 192,849 $ 318,445
Adjustments:
Restructuring initiatives 1,651 1,607 3,473 4,301
Net investment loss (gain) 764 122 876 (638 )
Realized gain on investments included in net investment loss (gain) above — — 66 —
Russia deconsolidation 60,376 — 60,376 —
Gain from remeasurement of equity method investment — (26,518 ) — (26,518 )
Transaction costs related to acquisitions — 566 63 824
Purchase accounting adjustments related to acquisitions and investments — 976 96 976
Other special items 2,307 3,322 8,084 3,322
Foreign currency effects (1) (308 ) 7,852
Adjusted Net Income Attributable to AptarGroup, Inc. $ 97,700 $ 107,694 $ 265,883 $ 308,564
Average Number of Diluted Shares Outstanding 64,147 66,630 64,373 67,043
Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 0.51 $ 1.92 $ 3.00 $ 4.75
Adjustments:
Restructuring initiatives 0.02 0.02 0.05 0.06
Net investment loss (gain) 0.01 — 0.01 (0.01 )
Realized gain on investments included in net investment loss (gain) above — — — —
Russia deconsolidation 0.94 — 0.94 —
Gain from remeasurement of equity method investment — (0.40 ) — (0.40 )
Transaction costs related to acquisitions — 0.01 — 0.01
Purchase accounting adjustments related to acquisitions and investments — 0.02 — 0.02
Other special items 0.04 0.05 0.13 0.05
Foreign currency effects (1) — 0.12
Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 1.52 $ 1.62 $ 4.13 $ 4.60
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.
AptarGroup, Inc.
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)
(In Thousands)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Net Cash Provided by Operations $ 167,598 $ 177,606 $ 389,778 $ 386,306
Capital Expenditures (69,006 ) (63,313 ) (191,965 ) (183,600 )
Proceeds from Government Grants — — — 3,308
Free Cash Flow $ 98,592 $ 114,293 $ 197,813 $ 206,014
AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data)
Three Months Ending December 31,
Expected 2026 2025
Income before Income Taxes $ 91,522
Adjustments:
Restructuring initiatives 4,048
Curtailment gain related to restructuring initiatives (115 )
Net investment loss 1,328
Transaction costs related to acquisitions 368
Purchase accounting adjustments related to acquisitions and investments 645
Other special items 3,960
Foreign currency effects (1) (2,485 )
Adjusted Earnings before Income Taxes $ 99,271
Provision for Income Taxes $ 17,252
Adjustments:
Restructuring initiatives 1,015
Curtailment gain related to restructuring initiatives (30 )
Net investment loss 325
Transaction costs related to acquisitions 125
Purchase accounting adjustments related to acquisitions and investments 110
Other special items 970
Foreign currency effects (1) (468 )
Adjusted Provision for Income Taxes $ 19,299
Net Loss Attributable to Noncontrolling Interests $ 130
Net Income Attributable to Redeemable Noncontrolling Interests $ (56 )
Net Income Attributable to AptarGroup, Inc. $ 74,344
Adjustments:
Restructuring initiatives 3,033
Curtailment gain related to restructuring initiatives (85 )
Net investment loss 1,003
Transaction costs related to acquisitions 243
Purchase accounting adjustments related to acquisitions and investments 535
Other special items 2,990
Foreign currency effects (1) (2,017 )
Adjusted Net Income Attributable to AptarGroup, Inc. $ 80,046
Average Number of Diluted Shares Outstanding 65,796
Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 1.13
Adjustments:
Restructuring initiatives 0.05
Curtailment gain related to restructuring initiatives —
Net investment loss 0.01
Transaction costs related to acquisitions —
Purchase accounting adjustments related to acquisitions and investments 0.01
Other special items 0.05
Foreign currency effects (1) (0.03 )
Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2) $1.39 - $1.47 $ 1.22
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates.
(2) AptarGroup’s expected adjusted earnings per share range for the fourth quarter of 2026, see non-GAAP section for full definition, is based on an effective tax rate range of 17.5% to 19.5%. This tax rate range compares to our fourth quarter of 2025 effective tax rate of 18.9% on reported earnings per share and 19.4% on adjusted earnings per share.

Investor Relations Contact:
Mary Skafidas
[email protected]

815-479-5530

Media Contact:
Katie Reardon
[email protected]

815-479-5671

Source: AptarGroup, Inc.

View All News

Aptar Logo

Follow us

X, twitter    linkedin    youtube    instagram    facebook

IR Contact

Investor Relations Department
AptarGroup, Inc.
265 Exchange Drive, Suite 301
Crystal Lake, IL 60014

​ 815-477-0424

​ [email protected]

Investor Email Alerts

Personal Information.

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

  • News
  • Quarterly Reports
  • Annual Reports
  • SEC Filings
  • End of Day Stock Quote
  • Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again. Submit

Unsubscribe

© 2026 Q4 Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

October 22, 2026

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, 2027.

Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business

Maes joins Aptar from Amcor, where she currently leads its global Flexibles Pharma and Medical packaging business, spanning North America, Latin America, EMEA and Asia. During her career at Amcor, she has held senior leadership roles across pharma, medical, strategy and business development. She brings extensive experience in global customer relationships, growth and transformation, operational performance and building highly engaged teams. Earlier in her career, Maes worked at McKinsey & Company, Terra Firma Capital Partners and Morgan Stanley. She holds an MBA from Harvard Business School, a Master’s in Financial Management from Vlerick Business School and a Master’s in Applied Economics from Ghent University.

“Virginie brings significant global experience, a strong customer focus and a proven ability to lead and grow complex businesses. I am confident she is the right leader to take our Pharma business forward,” said Gael Touya, President and Chief Executive Officer of Aptar. “She will lead a business with strong market positions, deep scientific and technical expertise and significant bench strength. Our focus is on continuing to become the partner of choice for our customers, solving their most complex challenges and creating value beyond the product.”

“I am excited to join Aptar and a Pharma business with strong leadership positions, deep expertise and a clear commitment to its customers,” said Virginie Maes. “The opportunity to work alongside our teams and customers to help them succeed, bringing together our technologies, services and expertise across the value chain from formulation through commercialization is what I’m most enthusiastic about. Ultimately, everything we do should be focused on helping our customers deliver solutions that support patients and improve their lives.”

About Aptar

Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com

.

Prompts

AptarGroup, Inc. (ticker ATR), listed in United States.

ETFs Holding AptarGroup, Inc.

ETF Weight in ETF Shares Market value As of
BEEZ 4.51% 1,962 $ 280K Nov 18, 2026
SMLL 2.40% 2,246 $ 321.38K Nov 13, 2026
NBSM 1.83% 15,994 $ 2.105M Aug 31, 2026
NRES 1.74% 4,957 $ 652.44K Aug 31, 2026
OSCV 1.29% 67,759 $ 9.077M Jul 31, 2026
SMCO 1.21% 12,396 $ 1.775M Nov 17, 2026
HSMV 1.18% 456 $ 65.286K Nov 16, 2026
FDIV 1.07% 4,697 $ 629.21K Jul 31, 2026
SSMG 1.01% 240 $ 32.15K Jul 31, 2026
KNOW 0.65% 357 $ 44.696K Jun 30, 2026
FEMV 0.55% 232 $ 29.046K Jun 30, 2026
PAPI 0.51% 16,213 $ 2.03M Jun 30, 2026
MCDS 0.42% 238 $ 33.399K Nov 17, 2026
DFAT 0.29% 650,132 $ 92.137M Nov 12, 2026
SDVD 0.22% 13,875 $ 1.985M Nov 11, 2026
AVMV 0.18% 10,700 $ 1.532M Nov 16, 2026
JMEE 0.17% 33,877 $ 4.754M Nov 17, 2026
SMDX 0.16% 1,427 $ 204.304K Nov 17, 2026
DFAS 0.14% 330,457 $ 46.832M Nov 12, 2026
SYZ 0.14% 764 $ 95.653K Jun 30, 2026
AVMC 0.10% 4,041 $ 578.55K Nov 16, 2026
IALT short -0.07% -37,940 $ -5.432M Nov 16, 2026
DXUV 0.05% 23,445 $ 3.323M Nov 12, 2026
DFUV 0.05% 52,448 $ 7.433M Nov 12, 2026
AVSU 0.04% 1,193 $ 170.802K Nov 16, 2026
AVUQ 0.04% 1,137 $ 162.784K Nov 16, 2026
DFSU 0.04% 6,720 $ 952.358K Nov 12, 2026
MSSM 0.04% 2,012 $ 264.819K Aug 31, 2026
DFAC 0.04% 226,478 $ 32.096M Nov 12, 2026
FMDE 0.04% 21,495 $ 2.691M Jun 30, 2026
AVUS 0.03% 26,287 $ 3.764M Nov 16, 2026
AVLC 0.03% 3,132 $ 448.408K Nov 16, 2026
JSTC 0.03% 518 $ 74.162K Nov 17, 2026
DCOR 0.03% 94,431 $ 13.383M Nov 12, 2026
ENHU 0.02% 15 $ 2,147.55 Nov 16, 2026
EBI 0.02% 985 $ 129.646K Aug 31, 2026
DFAU 0.02% 15,396 $ 2.182M Nov 12, 2026
DFUS 0.01% 19,660 $ 2.786M Nov 12, 2026
MSLC 0.01% 2,473 $ 325.496K Aug 31, 2026